FDAnews Drug Daily Bulletin

EISAI INC. RECEIVES SUMMARY JUDGMENT MOTION DECISIONS IN U.S. LEGAL ACTION OVER ACIPHEX ANDA FILINGS

Oct. 10, 2006
A A

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) announce that they received court decisions on ANDA-related summary judgment motions for Aciphex (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet) on October 6, 2006.

PR Newswire (http://sev.prnewswire.com/biotechnology/20061008/NYSU01809102006-1.html)